<unk> , sold under the brand name Rybrevant, is a bispecific antibody medication used to treat non-small cell lung cancer. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests.<unk>  is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.<unk>  was approved for medical use in the United States in May 2021.
Amivantamab
Glysobuzole
Glybuzole
Tirapazamine
Pivagabine
Valproate pivoxil
Influenzanet
Fosaprepitant